A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms

Cash, Brooks D.; Epstein, Michael; Shah, Syed M.

doi:10.1007/s10620-015-3858-7

Cited by 124 publications

(140 citation statements)

References 32 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Peppermint oil, which also inhibits smooth muscle contraction albeit by calcium channel blockade, is beneficial in reducing IBS symptoms 188 . A recent RCT in patients with IBS-D and IBS-M demonstrated that a novel formulation of peppermint oil, designed to cause a sustained release within the small bowel, was superior to placebo in causing a reduction in total symptoms 189 .…”

Section: Managementmentioning

confidence: 99%

Irritable bowel syndrome

Enck¹,

Aziz

Barbara

et al. 2016

Nat Rev Dis Primers

731

774

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with a high population prevalence. The disorder can be debilitating in some patients, whereas others may have mild or moderate symptoms. The most important single risk factors are female sex, younger age and preceding gastrointestinal infections. Clinical symptoms of IBS include abdominal pain or discomfort, stool irregularities and bloating, as well as other somatic, visceral and psychiatric comorbidities. Currently, the diagnosis of IBS is based on symptoms and the exclusion of other organic diseases, and therapy includes drug treatment of the predominant symptoms, nutrition and psychotherapy. Although the underlying pathogenesis is far from understood, aetiological factors include increased epithelial hyperpermeability, dysbiosis, inflammation, visceral hypersensitivity, epigenetics and genetics, and altered brain–gut interactions. IBS considerably affects quality of life and imposes a profound burden on patients, physicians and the health-care system. The past decade has seen remarkable progress in our understanding of functional bowel disorders such as IBS that will be summarized in this Primer.

show abstract

Section: Managementmentioning

confidence: 99%

Irritable bowel syndrome

Enck¹,

Aziz

Barbara

et al. 2016

Nat Rev Dis Primers

731

774

View full text Add to dashboard Cite

show abstract

“…Such events were, however, mild and transient in nature. A new formulation of peppermint oil with sustained release into the small bowel was tested in a small multicentre trial and showed no superiority over placebo,71 although pain, bloating and urgency were significantly reduced.…”

Section: Current Approaches To Manage Visceral Pain In Patients With Ibsmentioning

confidence: 99%

Dietary and pharmacological treatment of abdominal pain in IBS

Camilleri

Boeckxstaens

2017

Gut

119

122

View full text Add to dashboard Cite

This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain in functional GI diseases, principally IBS. These approaches include dietary measures including fibre supplementation, low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet, and pharmacological approaches such as antispasmodics, peppermint oil, antidepressants (tricyclic agents, selective serotonin reuptake inhibitors), 5-HT receptor antagonists (alosetron, ondansetron, ramosetron), non-absorbed antibiotic (rifaximin), secretagogues (lubiprostone, linaclotide), μ-opioid receptor (OR) and κ-OR agonist, δ-OR antagonist (eluxadoline), histamine H1 receptor antagonist (ebastine), neurokinin-2 receptor antagonist (ibodutant) and GABAergic agents (gabapentin and pregabalin). Efficacy and safety are discussed based on pivotal trials or published systematic reviews and meta-analysis, expressing ORs or relative risks and their 95% CIs. Potential new approaches may be based on recent insights on mucosal expression of genes, and microRNA and epigenetic markers in human biopsies and in animal models of visceral hypersensitivity.The objectives of this review are to appraise the physiology and anatomy of gut sensation and the efficacy in the relief of visceral pain (typically in IBS) of several classes of therapies. These include fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and different classes of medications (box 1). Box 1Classes of pharmacological agents for visceral painAntidepressants (tricyclic agents, selective serotonin reuptake inhibitors)Peppermint oil5-HT receptor antagonists (alosetron, ondansetron, ramosetron)Non-absorbed antibiotic (rifaximin)Secretagogues (lubiprostone, linaclotide)μ-Opioid receptor (OR) and κ-OR agonist and δ-OR antagonist (eluxadoline)Histamine H1 receptor antagonist (ebastine)Neurokinin-2 receptor antagonist (ibodutant)GABAergic agents (gabapentin and pregabalin).

show abstract

“…[37] In a short (4 weeks) study in 72 patients, peppermint oil, a TRPM8 agonist, was more effective than placebo in IBS-D and IBS-M; the unconventional primary endpoint was the change from baseline in the Total IBS Symptom Score (TISS) after 4 weeks of treatment. [38]…”

Section: Diarrhea and Diarrhea-predominant Ibs (Ibs-d)mentioning

confidence: 99%

Existing and emerging therapies for managing constipation and diarrhea

Bharucha

Wouters

Tack

2017

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (ie, constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.

show abstract

A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms

Cited by 124 publications

References 32 publications

Irritable bowel syndrome

Irritable bowel syndrome

Dietary and pharmacological treatment of abdominal pain in IBS

Existing and emerging therapies for managing constipation and diarrhea

Contact Info

Product

Resources

About